Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 5
---
 commercialization of our product candidates; |

| ● | the impact of the delisting of our Common Stock and public warrants from the NASDAQ Stock Market (“Nasdaq”); |

| ● | the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; |

| ● | the scope, progress, results and costs of developing CER-1236 or any other product candidates we may develop, and conducting preclinical studies and clinical trials; |

| ● | the timing and costs involved in obtaining and maintaining regulatory approval of CER-1236 or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations or accelerated approvals for our drug candidates for various indications; |

| ● | current and future agreements with third parties in connection with the development and commercialization of CER-1236 or any other future product candidate; |

| ● | our ability to advance product candidates into and successfully complete clinical trials; |

| ● | the ability of our clinical trials to demonstrate the safety and efficacy of CER-1236 and any other product candidates we may develop, and other positive results; |

<div align='center'>ii</div>

| ● | the size and growth potential of the markets for our product candidates, and our ability to serve those markets; |

| ● | the benefits of orphan drug designation and potential for orphan drug exclusivity in the future for CER-1236 and any other product candidates that may receive orphan drug designation; |

| ● | our plans relating to the commercialization of CER-1236 and any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales team; |

| ● | the success of competing drugs, therapies or other products that are or may become available; |

| ● | developments relating to our competitors and our industry, including competing product candidates and therapies; |

| ● | our plans relating to the further development and manufacturing of CER-1236 and any other product candidates we may develop, including additional indications that we may pursue for CER-1236 or other product candidates; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our potential and ability to successfully manufacture and supply CER-1236 and any other product candidates we may develop for clinical trials and for commercial use, if approved; |

| ● | the rate and degree of market acceptance of C